Clinical trials to begin on potent angiogenesis inhibitorsBMJ 1998; 316 doi: https://doi.org/10.1136/bmj.316.7142.1407 (Published 09 May 1998) Cite this as: BMJ 1998;316:1407
- Kamran Abbasi
Two new drugs that inhibit the blood supply to tumours are to undergo clinical trials in humans. A statement by the US National Cancer Institute that research on endostatin and angiostatin is “a high priority” sent the share price of the manufacturer of the drugs, Entremed, soaring and caused massive public interest.
In one day …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial